
In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications.
In today's ACT Brief, we examine governance inertia when AI accelerates protocol development, why payment experience is becoming a competitive differentiator for sites, and FDA approval of Caplyta for relapse prevention in schizophrenia.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
That's all for today's ACT Brief. Join us next time for more updates shaping clinical operations and drug development. Thanks for listening.







